- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06013995
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
February 22, 2024 updated by: Bristol-Myers Squibb
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus
The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain the NCT# and Site #.
Study Locations
-
-
Buenos Aires
-
Pilar, Buenos Aires, Argentina, 1629
- Not yet recruiting
- Local Institution - 0070
-
Contact:
- Site 0070
-
-
Ciudad Autónoma De Buenos Aires
-
Caba, Ciudad Autónoma De Buenos Aires, Argentina, C1430EGF
- Not yet recruiting
- Local Institution - 0075
-
Contact:
- Site 0075
-
-
-
-
Sofia (stolitsa)
-
Sofia, Sofia (stolitsa), Bulgaria, 1618
- Not yet recruiting
- Local Institution - 0072
-
Contact:
- Site 0072
-
-
-
-
-
Dessau, Germany, 06847
- Not yet recruiting
- Local Institution - 0071
-
Contact:
- Site 0071
-
-
-
-
-
Chihuahua, Mexico, 31217
- Not yet recruiting
- Local Institution - 0077
-
Contact:
- Site 0077
-
-
Distrito Federal
-
Cuauhtémoc, Ciudad De México, Distrito Federal, Mexico, 06100
- Not yet recruiting
- Local Institution - 0073
-
Contact:
- Site 0073
-
Mexico City, Distrito Federal, Mexico, 07760
- Not yet recruiting
- Local Institution - 0068
-
Contact:
- Site 0068
-
-
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 02-953
- Not yet recruiting
- Local Institution - 0069
-
Contact:
- Site 0069
-
-
Wielkopolskie
-
Poznan, Wielkopolskie, Poland, 61-848
- Not yet recruiting
- Local Institution - 0074
-
Contact:
- Site 0074
-
-
-
-
București
-
Bucharest, București, Romania, 11658
- Not yet recruiting
- Local Institution - 0065
-
Contact:
- Site 0065
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400006
- Not yet recruiting
- Local Institution - 0064
-
Contact:
- Site 0064
-
-
-
-
-
Cordoba, Spain, 14004
- Not yet recruiting
- Local Institution - 0045
-
Contact:
- Site 0045
-
-
-
-
California
-
San Diego, California, United States, 92108
- Recruiting
- TriWest Research Associates - La Mesa
-
Contact:
- Ara Dikranian, Site 0048
- Phone Number: 619-334-4735
-
-
Florida
-
Clearwater, Florida, United States, 33765
- Recruiting
- Clinical Research of West Florida, Inc. (Clearwater)
-
Contact:
- Robert Levin, Site 0055
- Phone Number: 727-466-0078
-
Tampa, Florida, United States, 33606
- Recruiting
- Clinical Research of West Florida
-
Contact:
- Shanmugapriya Reddy, MD, Site 0029
- Phone Number: 813-870-1292
-
-
Georgia
-
Lawrenceville, Georgia, United States, 30046
- Not yet recruiting
- North Georgia Rheumatology
-
Contact:
- Theresa Lawrence Ford, Site 0011
- Phone Number: 111-111-1111
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- Recruiting
- IMA Clinical Research Las Vegas
-
Contact:
- Rosaly Diaz-Torruellas, Site 0062
- Phone Number: 702-527-7401
-
-
New York
-
New York, New York, United States, 10032
- Withdrawn
- Columbia University Irving Medical Center
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Recruiting
- Altoona Center for Clinical Research
-
Contact:
- Alan Kivitz, Site 0005
- Phone Number: 814-934-4368
-
-
Texas
-
Allen, Texas, United States, 75013
- Withdrawn
- Allen Arthritis
-
Dallas, Texas, United States, 75231
- Withdrawn
- Metroplex Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Having a diagnosis of Discoid Lupus Erythematosus (DLE), Subacute Cutaneous Lupus Erythematosus (SCLE), or Systemic Lupus Erythematosus (SLE).
- Participants with DLE or SCLE must have their diagnosis at least 3 months prior to screening and must be confirmed by biopsy (except if only the facial/head/neck region is affected) and must have some ongoing disease activity (based CLASI-A scoring).
- Participants with SLE must have a diagnosis of SLE at screening based on the 2019 EULAR/ACR Classification for SLE and have mild-moderate disease severity (based on a SLEDAI-2K score).
Exclusion criteria:
- SLE that is considered by the Investigator to be severe.
- Drug-induced CLE and drug-induced SLE.
- Women who are pregnant or breastfeeding.
- Current use of >10 mg prednisone (or equivalent) per day.
Note: Other protocol-defined inclusion/exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A: BMS-986326 Dose 1 IV
|
Specified dose on specified days
Specified dose on specified days
|
Experimental: Cohort B: BMS-986326 Dose 2 IV
|
Specified dose on specified days
Specified dose on specified days
|
Experimental: Cohort C1: BMS-986326 Dose 3 IV
|
Specified dose on specified days
Specified dose on specified days
|
Experimental: Cohort C2: BMS-986326 Dose 3 SC
|
Specified dose on specified days
Specified dose on specified days
|
Experimental: Cohort D1: BMS-986326 Dose 4 IV
|
Specified dose on specified days
Specified dose on specified days
|
Experimental: Cohort D2: BMS-986326 Dose 4 SC
|
Specified dose on specified days
Specified dose on specified days
|
Experimental: Cohort E1: BMS-986326 Dose 3 IV
|
Specified dose on specified days
Specified dose on specified days
|
Experimental: Cohort E2: BMS-986326 Dose 3 SC
|
Specified dose on specified days
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events (AEs)
Time Frame: Up to 228 days
|
Up to 228 days
|
Number of participants with serious adverse events (SAEs)
Time Frame: Up to 228 days
|
Up to 228 days
|
Number of participants with clinical laboratory abnormalities
Time Frame: Up to 228 days
|
Up to 228 days
|
Number of participants with vital sign abnormalities
Time Frame: Up to 228 days
|
Up to 228 days
|
Number of participants with electrocardiogram (ECG) abnormalities
Time Frame: Up to 228 days
|
Up to 228 days
|
Number of participants with physical examination abnormalities
Time Frame: Up to 228 days
|
Up to 228 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum observed serum concentration (Cmax)
Time Frame: Predose and post-dose up to Day 167
|
Predose and post-dose up to Day 167
|
Time of Cmax (Tmax)
Time Frame: Predose and post-dose up to Day 167
|
Predose and post-dose up to Day 167
|
Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])
Time Frame: Predose and post-dose up to Day 167
|
Predose and post-dose up to Day 167
|
Change from baseline in regulatory T cells (Treg) count to Day 144
Time Frame: Baseline up to Day 144
|
Baseline up to Day 144
|
Change from baseline in Treg-to-conventional t cells (Tconv) ratio
Time Frame: Baseline up to Day 144
|
Baseline up to Day 144
|
Number of participants with anti-drug antibodies
Time Frame: Baseline up to Day 167
|
Baseline up to Day 167
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 21, 2023
Primary Completion (Estimated)
November 24, 2025
Study Completion (Estimated)
November 24, 2025
Study Registration Dates
First Submitted
August 23, 2023
First Submitted That Met QC Criteria
August 23, 2023
First Posted (Actual)
August 28, 2023
Study Record Updates
Last Update Posted (Actual)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 22, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- IM034-1000
- 2022-503009-39 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus
-
AmgenTerminatedSystemic Lupus Erythematosus | Cutaneous Lupus | Lupus | Discoid LupusUnited States
-
BiogenRecruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Italy, Korea, Republic of, Taiwan, Argentina, Chile, Spain, Canada, Serbia, France, Germany, Japan, Brazil, United Kingdom, Puerto Rico, Bulgaria, Portugal, Switzerland, Philippines, Saudi Arabia, Sweden, Mexico, Poland, Hunga... and more
-
BiogenEnrolling by invitationSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusFrance, Spain, United States, Sweden
-
Florida Academic Dermatology CentersUnknownDiscoid Lupus Erythematosus (DLE)United States
-
AmgenCompleted
-
Bristol-Myers SquibbActive, not recruitingLupus Erythematosus, Discoid | Lupus Erythematosus, Subacute CutaneousMexico, Argentina, Australia, United States, France, Germany, Poland, Taiwan
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
AmgenTerminatedCutaneous Lupus | LupusUnited States, Australia, Canada
-
LEO PharmaTerminatedDiscoid Lupus ErythematosusUnited States, France, Germany, Denmark
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
Clinical Trials on BMS-986326
-
Bristol-Myers SquibbNot yet recruiting
-
Bristol-Myers SquibbActive, not recruitingHealthy ParticipantsGermany
-
CelgeneRecruitingProstatic NeoplasmsUnited States
-
Bristol-Myers SquibbCompletedHeart FailureUnited States
-
Bristol-Myers SquibbRecruitingProgressive Pulmonary FibrosisChina, United States, Japan, Korea, Republic of, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Netherlands, Peru, Poland, Portuga... and more
-
Bristol-Myers SquibbRecruitingIdiopathic Pulmonary FibrosisChina, Taiwan, United States, Australia, Japan, United Kingdom, Korea, Republic of, Israel, Canada, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedHeart Decompensation, AcuteUnited States
-
China National Center for Cardiovascular DiseasesPeking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...UnknownCoronary Artery EctasiaChina
-
Dana-Farber Cancer InstituteStand Up To CancerActive, not recruitingLymphoma | Solid Tumor, Childhood | Brain Tumor, PediatricUnited States, Canada